This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults. Sixty-eight patients were included in the trial between October 2008 and December 2010. The median age was 49 years, with 28 patients >55 years of age. Sixty-five patients achieved CR (95.6%). The estimated 2-year event-free survival (EFS) and overall survival (OS) were 62.3% and 67.4%, respectively. Allogeneic stem cell transplantation (allo-SCT) at initial CR was performed in 43 patients. Thirty-five of 39 patients <55 years and 8 of 26 patients >55 years underwent allo-SCT at first CR. The 3-year OS in patients <55 years receiving allo-SCT at first CR, patients >55 years receiving allo-SCT at first CR, patients <55 years not receiving allo-SCT at first CR, and patients >55 years not receiving allo-SCT at first CR were 80.4%, 41.1%, 32.5%, and 52.0%, respectively (P 5 0.058). The three-year EFS in each group was 76.7%, 53.6%, not reached, and 26.4%, respectively (P 5 0.150). A high CR rate was observed with imatinib-based chemotherapy allowing allo-SCT in a high proportion of patients, particularly those <55 years. Moreover, intensified consolidation therapy reduced early relapse rates following induction therapy and resulted in improved OS and EFS rates following allo-SCT. This trial was registered with the UMIN
| I N T R O D U C T I O N
Philadelphia chromosome-positive acute lymphoblastic leukemia (Phpositive ALL) usually arises from a t(9;22)(q34;q11.2) translocation that results in BCR-ABL fusion; it is more common in older patients (25%-35%) and is frequently associated with leukocytosis. 1 The Japan Adult Leukemia Study Group (JALSG) studies reported low complete remission (CR) rates of 51%-64% following chemotherapy in Phpositive ALL cases as well as extremely low survival rates due to early relapse, even in cases where CR was achieved. [2] [3] [4] [5] The introduction of imatinib dramatically altered treatment strategies for Phpositive ALL. 6, 7 At the MD Anderson Cancer Center (MDACC), combined treatment with imatinib and Hyper-CVAD resulted in a high CR of 93% and a 5-year survival rate of 43%. 8 We recently reported the clinical results for the JALSG ALL202 study at the 51th American Society of Hematology (ASH) Annual Meeting. 9 The overwhelming majority of patients (97.1%) achieved CR with a 9% relapse rate within 100 days of CR. However, the problem with this regimen appeared to be the high incidence of relapse; we had to evaluate ways for improving survival. To improve survival, treatment intensity had to be increased and the protocol needed to be revised with a more potent treatment regimen during the induction and consolidation periods. We now report the results of a subsequent study (the JALSG Ph 1 ALL208 study) evaluating the utility of a modified consolidation therapy for preventing early relapse after the attainment of CR in patients with Ph 1 ALL.
| P A T I E NT S A ND M E T H O DS

| Patients
Patients between 15 and 64 years of age with previously untreated newly diagnosed Ph-positive ALL were included in this study. Eligibility criteria included adequate liver function (serum bilirubin level <2.0 mg/ dL), kidney function (serum creatinine level <2.0 mg/dL), and heart function (absence of severe abnormalities on electrocardiogram), and an Eastern Cooperative Oncology Group performance status between 0 and 3. Written informed consent was obtained from all patients prior to their registration in the study.
| Treatment regimen
The JALSG Ph 1 ALL208 study was a prospective, nonrandomized, phase 2 trial in patients newly diagnosed with BCR-ABL-positive ALL.
All BCR-ABL-positive patients were treated with the regimen presented in Supporting Information resumed at a dose of 600 mg/day after a recovery to grade 2 or better.
In cases of nonhematologic toxicity during maintenance courses, we used a procedure similar to the one used for remission induction courses.
| Response and outcome definitions
CR was defined as the presence of all of the following: less than 5% of blasts in bone marrow aspirates, no evidence leukemic blasts in peripheral blood, recovery of peripheral blood values to neutrophil counts of at least 1000/lL and platelet counts of at least 100 000/lL, and no evidence of extramedullary leukemia. Relapse was defined as the presence of at least one of the following: recurrence with greater than 10% leukemic cells in bone marrow or the presence of any leukemic cells in the peripheral blood or at extramedullary sites. Toxicity evaluations were based on the National Cancer Institute Common Toxicity Criteria Version 3.0. Event-free survival (EFS) was defined as the time from the first day of therapy to induction failure, relapse, death, or last study visit. Overall survival (OS) was defined as the time from the first day of therapy to death or last study visit.
| Minimal residual disease
The bone marrow BCR-ABL copy number was assessed using real-
Inc., Tokyo) at the following points: after the remission induction course, after the first, second and fourth cycles of C2, and at the end of therapy. In addition, in patients who received allo-SCT, the bone marrow BCR-ABL copy number was assessed prior to the conditioning therapy, at 3 months, and at 1 year after allo-SCT. Total RNA was extracted from the mononuclear cells and transcribed to cDNA according to the manufacturer's instructions. RQ-PCR assays were performed using Taq Man technology (PE Biosystems, Foster City, CA). The primers and detection probes used in this study have been previously described. 10 The number of transcript copies was normalized for glyceraldehyde 3-phosphate dehydrogenase expression and converted into molecules/lg RNA. The threshold for quantification was 50 copies/lg RNA, corresponding to a sensitivity of 10
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. Transcript levels below the threshold were differentiated into "not detected" and "detected but not quantifiable" with PCR negativity categorized as the former.
| Statistical methods
The primary end point of this study was EFS. The CR rates, toxicity, survival, minimal residual disease (MRD), and allo-SCT were used as secondary end points. We estimated the required sample size of this study based on the results of the JALSG ALL202 study in which we had applied similar eligibility criteria in recruitment. In the JALSG ALL202 study, the 2-year EFS was 49%, and for patients who had received an allo-SCT during the first CR, the 2-year EFS was 63%.
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We set an expected 2-year EFS of 60% for this trial and a threshold 2- Table 1 . An allo-SCT at initial CR was performed in 43 patients (63%) (13 from a related donor, 23 from an unrelated bone marrow donor, and 7 from unrelated cord blood) at a median of 6 months (3-14 months) from diagnosis. Thirty-five of the 39 (90%) cases <55 years and 8 of the 26 (31%) cases >55 years of age underwent an allo-SCT at first CR. Twenty-two patients did not receive an allo-SCT at first CR; of these, two received an allo-SCT at a second CR and two received allo-SCT during active disease. The median time from diagnosis to an allo-SCT was 172 days (78-415 days).
| Response
| Relapse
A total of 18 patients relapsed at a median of 404 days (144-1110 days) after achieving CR. In the 22 patients who did not receive an allo-SCT at first CR, 12 patients had relapsed at a median of 352 days (144-1110 days) after achieving CR. In the 43 patients who received an allo-SCT at first CR, 6 patients had relapsed at a median of 351 days (152-612 days) after allo-SCT.
| Follow-up and outcomes
The median follow-up period was 34 months (13.4-52.8 months) for surviving patients. The estimated 3-year OS and EFS were 62% [95% confidence interval (CI), 49%-72%] and 52% (95% CI: 37%-66%), respectively ( Figure 1 ). The 3-year OS and EFS in patients who received an allo-SCT at first CR were 75% (95% CI: 57%-86%) and 72% (95% CI: 56%-83%), respectively. The estimated cumulative incidence of relapse and nonrelapse mortality (NRM) at 1 year were 12.6% (95% CI: 7.5%-19.0%) and 17.3% (95% CI: 11.3%-24.3%), respectively.
On the other hand, the 3-year OS and EFS in those who did not receive an allo-SCT at first CR were 40% (95% CI: 21%-58%) and 21% an allo-SCT at first CR (74%, 95% CI: 56%-85% vs. 48%; 95% CI: 27%-67%; P 5 0.118), but the 3-year EFS was marginally preferable in patients who received an allo-SCT at first CR (73%; 95% CI: 57%-84%
vs. 28%, 95% CI: 6%-56%; P 5 0.0575) compared to the overall values.
The three-year OS in patients <55 years of age with an allo-SCT at first CR (n 5 35), patients >55 years of age with allo-SCT at first CR (n 5 8), patients <55 years of age without allo-SCT at first CR (n 5 4), and patients >55 years of age without allo-SCT at first CR (n 5 18)
were 80% (95% CI: 61%-91%), 41% (95% CI: 9%-72%), 32% (95% CI:
1%-75%), and 48% (95% CI: 26%-68%), respectively (P 5 0.058; Figure   2c and d). The 3-year EFS in each group were 77% (95% CI: 59%-88%), 54% (95% CI: 13%-83%), not reached, and 26% (95% CI: 6%-54%), respectively; the difference did not reach statistical significance (P 5 0.1498). With regard to the clinical outcome after allo-SCT at first CR, the OS and EFS at 3 years after SCT were 75% (95% CI: 57%-86%) and 71% (95% CI: 55%-83%), respectively. The 3-year OS and EFS after allo-SCT at first CR in patients <55 years of age were 81% (95% CI: 62%-91%) and 77% (95% CI: 59%-88%), respectively. Maintenance therapy was administered to 10 patients, none of whom underwent allo-SCT. Of the 10 patents, 4 patients exhibited relapse, of these, 2 patients died and 2 survived. The remaining 6 patients experienced relapse-free survival, and 3 patients continued to show the PCR negativity.
| Toxicity/cause of death
The severe toxicity associated with remission induction therapy was not different from that observed with conventional chemotherapy. For patients who attained CR, the median time to a neutrophil recovery of at least 500/lL from treatment initiation was 13 days Twenty-five patients died due to disease progression (n 5 12), complications during the remission induction course (n 5 3), complications during the first CR (n 5 4, 2 sepsis and 2 pneumonia), and transplant-related causes (n 5 6).Three deaths occurred during the remission induction course, four deaths occurred during first CR (sepsis; 2 cases, pneumonia; 2 cases), and five deaths were due to disease relapse. Thirteen deaths occurred after an allo-SCT; seven deaths were due to relapse or disease progression, and six deaths were due to transplant-related mortality (TRM). In the present study, 4 of the 39 cases <55 years of age did not receive an allo-SCT during the first CR. Four patients relapsed or died before an allo-SCT by an appropriate donor. One death occurred during consolidation therapy, and three patients relapsed after consolidation therapy.
| Relationship between MRD and clinical result after allo-SCT
Data regarding the MRD status could be accessed after the remission induction coursefor 53 of 68 patients; 20 (38%) patients achieved PCR negativity. After the C1 course, of the 45 patients in whom the MRD status could be accessed, 26 (58%) patients achieved PCR negativity.
There was no significant relationship between PCR negativity (postremission induction, post-C1) and the cumulative incidence (CI) of relapse rate (P 5 0.1724 and P 5 0.5782, respectively). Of the 43 patients who received an allo-SCT at first CR, data regarding MRD status after the remission induction courseand before allo-SCT were available in 36 (84%) and 25 (58%) patients, respectively. Of these, 13 (36%) patients achieved PCR-negativity after the remission induction course and 20 patients (80%) achieved PCR negativity before allo-SCT. The CI of relapse after an allo-SCT was marginally related with the PCR negativity after the remission induction course (P 5 0.0510), and not significantly related with that before allo-SCT (P 5 0.1513).
| DISCUSSION
This study indicated a better OS and EFS in patients with Ph 1 ALL in the Ph 1 ALL208 trial that included an intensified consolidation course with concurrent schedules of imatinib and chemotherapy. In the JALSG ALL97 study, which was performed in the preimatinib era, 65 of 116 (56%) achieved CR, and 22 of these (19%) underwent allo-SCT in their first CR (19 from a related donor and 3 from an unrelated donor). 13 The Ph 1 ALL202 study was the first study to include imatinib administration; imatinib was administered from Day 8 to Day 63 in combination with other anticancer agents during the remission induction therapy. Ninety-seven percent of patients achieved CR, and 60% of patients underwent allo-HSCT at their first CR. OS for the entire group at 3 years was 57%. 4, [9] [10] [11] In the Ph 1 ALL202 study, good outcomes were observed; however, during the median observation period of 27 months, 28 of the 97 patients in remission relapsed, indicating that inhibition of relapse is a major issue. In the PhALL 1 202 study, consolidation therapy consisted of a course of high-dose MTX and high-dose Ara-C (C1), followed by imatinib alone for 28 days (C2); C1 and C2
were alternatively repeated for four cycles. Of the 17 patients who relapsed during consolidation therapy, 13 patients were undergoing C2
therapy. This suggests that consolidation therapy courses with imatinib alone are problematic. Wassmann et al. reported that the concurrent use of imatinib with chemotherapy resulted in a significantly superior rate of MRD-negative conversions and increased the 2-year survival rate by 7%. 7 Taking these results into account, the duration of imatinib monotherapy was reduced in the Ph 1 ALL208 study in the hope that this would improve survival during consolidation therapy because of the increase in dose intensity with chemotherapy and imatinib. In the present study, for remission induction therapy, imatinib was adminis- of patients received allo-SCT at their first CR. The 3-year OS and EFS were 62% and 52%, respectively. In particular, in young patients (age <55 years), most patients (90%) received an allo-SCT at the first CR.
Imatinib-based therapy has increased the proportion of patients who achieved sustained remission, thus allowing a higher proportion of patients to receive an allo-SCT. The present study might also enhance the merit of imatinib-based therapy compared with the previous JALSG Ph 1 ALL202 study.
Previously, we reported that the use of imatinib prior to allo-SCT was independently associated with post-transplantation survival rates, relapse rates, and nonrelapse mortality. 14 Imatinib combined with chemotherapy followed by allo-SCT has been considered as the standard of care for young patients with Ph 1 ALL. In the Ph 1 ALL202 study, OS and disease-free survival (DFS) at 3 years after allo-SCT were 64% and 58%, respectively. 15 In the present study, patients who received allo-SCT also had more promising outcomes for 3-year OS and EFS after receiving an allo-SCT (75% and 71%, respectively).
Young patients particularly achieved encouraging survival rates (81%).
On the other hand, 41% of patients were 55 years of age or older (elderly patients) in the present study. The 3-year EFS for patients who had received an allo-SCT at the first CR was not altogether satisfactory, but was better (although not statistically significant) than that for patients who had not received an allo-SCT (54% vs. 26%, respectively).
These findings probably contributed to the positive overall outcomes observed in the present study.
The measurement of MRD is essential for determining treatment effects and predicting prognosis in Ph 1 ALL. However, previous studies have reported conflicting results regarding the effects of postremission induction therapy and the presence of MRD on prognosis. [16] [17] [18] [19] [20] In the present study, PCR-negativity was achieved in 38% of patients after the remission induction course and 58% of patients after the C1 course. However, we could not find any significant relationship between the MRD status and clinical relapse. Thus, long-term observational studies with larger sample sizes may be required to fully evaluate the relationship between MRD and prognosis.
Ravandi et al. reported that durable remissions and long-term survival could be achieved with the combination therapy of chemotherapy and dasatinib in patients with Ph 1 ALL. 21 In that study, 65% of patients achieved complete molecular remission, and another 28% achieved a major molecular response at a median of 4 weeks after the initiation of treatment. Grades 3 and 4 adverse events included bleeding, pleural effusions, pericardial effusions, reversible rises in creatinine, deep vein thromboses, and pulmonary emboli as well as diarrhea, infections, hypophosphatemia, hypokalemia, hypocalcemia, hyperglycemia, and elevated transaminases. With a median follow-up of 67 months for the surviving patients, 46% patients were alive, and 43% remained in CR1. The median age of the patients was 55 years (range: 21-80 years), and 46 patients were older than 50 years. Therefore, only12 patients underwent allo-SCT in CR1. They mentioned that the persistence of MRD beyond 3 months of therapy with hyper-CVAD plus tyrosine kinase inhibitor based regimens could be associated with a lower likelihood of long-term success. 20 Thus, allo-SCT in younger patients appears to be beneficial in the remission phase.
To assist in the proper interpretation of our current results, we need to consider the strengths and limitations of our study. One of the strengths of this study was the relatively large sample size of the consecutive prospective clinical trials in Japan, which provided us a better estimation of the end points and also added statistical power to the analyses. One of the possible limitations of our current analysis could be the presence of residual confounding factors both known and unknown. First, we did not perform an exhaustive analysis of the relationship between clinical outcomes and MRD because of the lack of MRD data at each point (15/68 after induction therapy, 20/65 after C1, and 25/43 before allo-SCT). We believed that the powerful antileukemic activity of the imatinib-based therapy contributed to the subsequent relapse prevention in the present analysis, but we could not find any significant difference between the MRD status and relapse rate. Second, the results of the Ph 1 ALL208 study demonstrated improvements in the safety and efficacy of allo-SCT. The TRM rate of 14% (6 patients) in this study resulting from an allo-SCT during the first remission phase indicated that allo-SCT remains a high-risk treatment method. Despite the small number of patients 55 years of age or older who underwent allo-SCT during the first remission phase in the Ph 1 ALL208 study (8 patients), a 3-year OS of 41.4% is unacceptable.
Moreover, the development of treatment strategies will be required for patients >55 years of age, or <55 without an adequate donor, when allo-SCT may not be possible.
| C O NC LU S I O N
The present study demonstrated that the imatinib-combined chemotherapy regimen, JALSG Ph 1 ALL208, was effective and feasible. The regimen could help more than 90% of the patients who were less than 55 years old and achieved excellent therapeutic outcomes.
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